Preoperative Anemia as a Simple Prognostic Factor in Patients with Urinary Bladder Cancer

EF 1 Cheng Chen*
BDF 1 Linkun Hu*
BC 2 Xiangxiang Li
AC 1 Jianquan Hou

* These authors contributed equally to this work

Corresponding Author: Jianquan Hou, e-mail: houjianquan@suda.edu.cn

Source of support: Supported by the National Natural Science Foundation of China (No. 81272839)

Background: To evaluate the incidence of preoperative anemia and its prognostic role in patients with urinary bladder cancer (BC).

Material/Methods: A total of 317 patients diagnosed with BC were enrolled in this retrospective cohort study. Univariate and multivariate analysis was used to identify independent prognostic factors and Kaplan-Meier survival analysis was applied to examine the influence of anemia on survival.

Results: 109 patients (34.4%) were anemic with a median preoperative hemoglobin of 114 g/L (interquartile range 104 to 122.5). After a median of 6 years follow-up (range: 2 to 8 years), the median recurrence-free survival (RFS), progression-free survival (PFS), and overall survival (OS) in anemic patients were significantly lower than non-anemic patients \((p<0.001)\). Multivariate Cox analysis indicated that anemia remained an independent predictor of RFS and OS \((p=0.010, 0.007)\).

Conclusions: Anemic patients with BC are likely to have a shorter RFS and OS than non-anemic patients, and anemia is an independent predictor of RFS and OS.

MeSH Keywords: Anemia • Prognosis • Urinary Bladder Neoplasms

Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/902855
**Background**

Anemia is the most persistent and common disease detected in cancer patients with cancer. European Cancer Anemia Survey reported 31% of patients with cancer were anemic preoperatively in 2004, with levels of hemoglobin (HB) <12.0 g/dL prior to treatment [1].

The causes of preoperative anemia in cancer patients are multifactorial, but main causes are the neoplastic processes (which may lead to vitamin B12 and iron deficiency) and erythropoietin (EPO) reduction (as anemia may also be a side effect of treatment modalities including surgery, radiotherapy or chemotherapy) [2].

The recommended treatments for anemia in cancer patients include oral iron supplements, erythropoietins, and erythrocyte transfusions. Unfortunately, despite the high incidence and prevalence of anemia, only 40% of anemic patients received related therapy at any time during the survey period [1]. In some centers, treatments were initiated only when the HB value less than 9.7 g/dL [1].

Several studies have indicated that anemia is associated with poor prognosis in many cancers. Socinski et al. [3] reported that baseline HB, performance status (PS), and the use of combined modality therapy, have a significant effect on outcome in stage III non-small-cell lung cancer. Henry et al. [4] also reported that throughout treatment with erythropoietic-stimulating agents, patients with cancers whose HB values were less than 120 g/L had a worse oncological outcome than those with higher HB values.

Urinary bladder cancer (BC) is the most prevalent cancer in the urological tract [5]. Older men who present with frequent hematuria (grossly visible or microscopic) are more susceptible to anemia [6]. In BC patients, preoperative anemia is often exacerbated by potential hemorrhage after transurethral resection of bladder tumor (TURBT) or radical cystectomy (RC) and myelosuppressive treatment in patients who are undergoing intensive chemotherapy and radiotherapy. Preoperative anemia was reported to be a more severe prognosis indicator in BC patients undergoing RC [7–9], metastatic transitional cell carcinoma of the urothelial tract [10], and even in patients with urothelial carcinoma of the upper urinary tract [11].

Anemia can be detected using a simple and reliable test, so physicians treating patients with BC should be aware of the HB status of patients during treatment and follow-up. Monitoring HB levels may allow prediction of recurrence-free survival (RFS) and overall survival (OS).

**Material and Methods**

This study was approved by Soochow University for Clinical Investigation ethics committee. A retrospective cohort analysis was conducted in patients with newly diagnosed and pathologically confirmed BC and follow-up data at the First Affiliated Hospital of Soochow University between May 2007 and March 2016. Patients with other systemic disorders or malignancies were excluded. All clinical, laboratory, and pathological data were obtained from the urology and pathology departments. Pathological stages and grades were adjusted in accordance with the 7th edition of the TNM classification system and WHO 2004 grading system [12].

The patients were followed regularly for the following five years. Cystoscopy, renal ultrasound, urinary cytology, and CT scan were reviewed. RFS, PFS, and OS were considered for the period between the first tumor diagnosis and recurrence, progression or death, with censoring at the last follow-up visit.

Patients were categorized into two groups: anemic and non-anemic, based on HB level based on the World Health Organization (WHO) classification (male and female patients with <130 and <120 g/L HB, respectively) [13]. Non-muscle-invasive bladder cancer (NMIBC) comprises stage Ta and T1 tumors, and muscle-invasive bladder cancer (MIBC) comprises stage T2, T3, and T4 tumors. Patients of both groups were undergoing standard TURBT, RC, chemotherapy or radiotherapy, according to the European Association of Urology (EAU) guidelines [12].

**Statistical analyses**

The Kolmogorov-Smirnov test was applied to examine whether or not the acquired data were normally distributed. Data are presented as the means ± standard deviations (SD) and medians (IQR) for normally distributed variables. The Student’s two-sample t-test was used for normally distributed data and Mann-Whitney U test was used for uneventfully distributed data. Categorical variables were presented as percentages and analyzed by the Chi-square test and Fisher’s exact test.

The Kaplan-Meier method was applied to calculate survival in BC patients, the log rank test were using to estimate the differences in RFS, PFS, and OS probabilities. The statistical significance of the relationship between survival and each variable was analyzed using the Cox model. Proportional hazards assumptions were evaluated by testing the significance of time-dependent interaction terms for all variables. Predictive accuracy calculations of Cox regression models were quantified using the Harrell’s concordance index [14] and compared by the Mantel-Haenszel test. The correlation of anemia with albumin and hypersensitive C-reactive protein (hs-CRP) was evaluated by Spearman rank correlation analysis.
Statistical analyses were performed using SPSS version 21 (IBM, Chicago, IL, USA), R (version 3.0.0, The R Foundation for Statistical Computing, Vienna Austria) and a two-sided p value <0.05 was considered statistically significant.

Results

Patient characteristics

A total of 317 patients were included in this retrospective cohort study. The distribution of the baseline preoperative clinical and laboratory characteristics in the anemia group and non-anemic group at primary diagnosis are listed in Table 1. The study cohort comprised 260 male patients (82%). The median age of patients was 70 years (IQR 61–77). The median preoperative HB was 13.2 g/L (IQR 11.7, 14.3). A total of 109 patients (34.4%) had preoperative anemia, with median HB was 114 g/L (IQR 104, 122.5). All patients were pathologically diagnosed with bladder urothelial carcinoma without distant metastasis.

Univariate and multivariate survival analysis

Twelve potential prognostic factors were examined using Cox regression, and their association with RFS, PFS and OS were compared using univariate and multivariate survival analysis (Table 2). Univariate analysis identified four variables significantly associated with survival, which were thus included in multivariate model (Table 3). Anemia was strongly associated with RFS and OS (p=0.010, 0.007), but was not significantly associated with PFS (p=0.067). Meanwhile, Tumor T stage was significantly associated with PFS and OS (p=0.011, 0.049). The base model for predicting OS included albumin, hs-CRP, and tumor T stage, and the base model for predicting RFS included hs-CRP, and tumor T stage. The respective c-indices for RFS and OS were 0.93 and 0.79. Integration of HB levels significantly increased the predictive accuracies for RFS and OS to 0.94 and 0.87, respectively.

Survival analysis

A prognostic study of 317 patients followed up for a median of six years (range: 2 to 8 years). Seventy-four patients died within the group of 317 patients. Kaplan-Meier curves and median RFS, PFS and OS were calculated for the 317 patients.

As shown in Figure 1, the median RFS, PFS and OS of anemic patients with all stages of BC were significantly lower than those of non-anemic patients (p<0.001), and in Figure 2, when stratified by T stage, the median RFS, PFS and OS of anemic patients with NMIBC were significantly lower than those of non-anemic patients (p<0.001). However, in patients with MIBC, the median RFS, PFS, and OS did not differ significantly between anemic and non-anemic patients (p=0.652, 0.633, 0.365, respectively).

As shown in Figure 3, when stratified by albumin and Hs-CRP, patients with all stages of BC having low albumin or high Hs-CRP values had a worse prognosis than those with normal albumin or Hs-CRP values (p<0.05). Rank correlation analysis indicated that anemia and albumin were significantly positively correlated (r=0.399; p<0.001), and anemia and Hs-CRP were significantly negatively correlated (r=-0.196; p=0.001)

Discussion

Anemia is often identified at diagnosis or after treatment of tumors [15]. Baseline anemia in patients with cancer may be triggered by lack of nutrients, such as vitamin B12 and iron; depressed levels of trophic hormones such as EPO; concurrent infection or inflammation; hematuria; immunoreaction to tumor cells; and/or overexpression of certain inflammatory cytokines which reduce survival of red blood cells, suppress erythroid progenitor cells, and impair iron utilization and erythropoietin production, ultimately disrupting normal erythropoesis [16]. After surgery, anemia can be worsened by extensive blood loss during surgery, or adjuvant chemotherapy and/or radiotherapy

A large body of evidence suggests that anemia, one potential cause of tumor hypoxia, can affect cancer patients’ quality-of-life and treatment outcomes, including survival [17]. A large-sample meta-analysis also confirmed that anemia was correlated with cancer patient survival [18]. Oxygen is an important factor influencing tumor occurrence and development. Hypoxia is often observed within solid tumors, and is an independent marker of poor prognosis. Hypoxia can induce alterations in gene expression, cellular changes and a down-regulation of cell surface integrin to favor unrestricted tumor growth. These changes can produce a more clinically aggressive phenotype, and favor resistance to radiotherapy and chemotherapy [19]. Anemia can also affect tumor growth by inducing expression of cytokines involved in angiogenesis, such as vascular endothelial growth factor, which has been reported to be associated with low HB levels [20].

Preoperative anemia levels were shown to strongly related to postoperative complications and mortality in patients undergoing surgery [21]. Anemia was previously reported to be independently associated with shorter survival in cancer patients treated with chemotherapy or radiotherapy [22]. Several clinical studies have suggested that even mild anemia has a significant impact on patients’ oncological outcomes [23]. Therefore, correction of anemia, to complement iron agent
| Variables               | Overall patients | Anemia group | Non-anemic group | P value |
|-------------------------|------------------|--------------|------------------|---------|
| No. of patients (%)     | 317 (100%)       | 109 (34.4%)  | 208 (65.6%)      |         |
| Age (years)             | 70 (61–77)       | 70.71±10.68  | 68.24±11.35      | 0.062   |
| Gender (male (%))       | 260 (82%)        | 93 (85.3%)   | 167 (80.3%)      | 0.268   |
| Smoking (%)             | 46 (14.5%)       | 32 (15.4%)   | 14 (12.8%)       | 0.616   |
| Hypertension (%)        | 132 (41.6%)      | 46 (41.3%)   | 46 (42.2%)       | 0.905   |
| Diabetes mellitus (%)   | 30 (9.5%)        | 20 (9.6%)    | 10 (9.2%)        | 1       |
| RBC (10^12/L)           | 4.345 (3.84–4.70)| 3.71 (3.44–4) | 4.57 (4.30–4.81) | <0.001  |
| HB (g/L)                | 134 (120–145)    | 114 (104–122.5) | 142 (134.25–150) | <0.001  |
| HCT (L/L)               | 0.4 (0.36–0.43)  | 0.34 (0.32–0.36) | 0.42 (0.40–0.44) | <0.001  |
| MCV (fl)                | 92.3 (89.1–95.4) | 92.40 (87.35–95.95) | 92.30 (89.70–95.20) | 0.486   |
| RDW (%)                 | 13 (12.5–13.6)   | 13.20 (12.65–14.10) | 12.90 (12.40–13.40) | <0.001  |
| Albumin (g/L)           | 41.71±4.81       | 38.83±4.88   | 43.16±4.07       | <0.001  |
| WBC (10^9/L)            | 5.99 (4.97–7.30) | 5.72 (4.79–7.19) | 6.15 (5.01–7.35) | 0.241   |
| Hs-CRP (mg/L)           | 1.75 (0.67–5.14) | 3.46 (0.94–8.29) | 1.39 (0.59–3.69) | 0.001   |
| Stage at initial diagnosis (%) | 63 (19.9%) | 19 (17.4%) | 44 (21.2%) | 0.013   |
| Ta                      | 61 (19.2%)       | 14 (12.8%)   | 47 (22.6%)       |         |
| T1                      | 223 (71.5%)      | 46 (42.2%)   | 77 (37%)         |         |
| T2                      | 53 (16.7%)       | 18 (16.5%)   | 35 (16.8%)       |         |
| T3                      | 11 (3.5%)        | 8 (7.3%)     | 3 (1.4%)         |         |
| T4                      | 6 (1.9%)         | 4 (3.7%)     | 2 (1.0%)         |         |
| Tumor stage (%)         |                  |              |                  | 0.225   |
| Non-muscle invasive     | 184 (58%)        | 60 (55%)     | 124 (59.6%)      |         |
| Muscle invasive         | 70 (22.1%)       | 30 (27.5%)   | 40 (19.2%)       |         |
| Regional lymph node (%) |                  |              |                  | 0.574   |
| No                      | 246 (77.6%)      | 86 (78.9%)   | 160 (76.9%)      |         |
| N1                      | 2 (0.9%)         | 2 (1.8%)     | 1 (0.5%)         |         |
| N2                      | 5 (1.6%)         | 2 (1.8%)     | 3 (1.4%)         |         |
| Grade at initial diagnosis (%) | 57 (18%) | 24 (22.0%) | 33 (15.9%) | 0.402   |
| Low maglignant potential | 6 (1.9%)    | 2 (1.8%)     | 4 (1.9%)         |         |
| Low grade               | 36 (11.4%)       | 9 (8.3%)     | 27 (13.0%)       |         |
| High grade              | 218 (68.8%)      | 74(67.9%)    | 144 (69.2%)      |         |
| Recurrence rate (%)     |                  |              |                  | 0.248   |
| ≤1                      | 269 (84.9%)      | 96 (88.1%)   | 173 (83.2%)      |         |
| >1                      | 48 (15.1%)       | 13 (11.9%)   | 35 (16.8%)       |         |
or promote red element, may have a positive impact on cancer patients’ treatment outcomes [24]. These findings underscore the need to incorporate diagnosis and treatment of anemia into routine management of cancer patients. Optimal management of anemia appears to be a critical component of cancer treatment.

The main finding of this study confirms that preoperative anemia as an independent predictor of RFS and OS in BC patients. Standard clinical and pathological risk factors, such as tumor stage, were also found to be independent predictors of disease progression, and were associated with BC patient mortality. The negative association between preoperative anemia and the main outcomes of interest (RFS and OS) suggests that identifying and managing anemia early in the course of BC treatment could lead to improved patient outcomes.

### Table 2. Results of univariate analyses.

| Variable at baseline | Recurrence-free survival | Progression-free survival | Overall survival | P value |
|----------------------|--------------------------|---------------------------|-----------------|---------|
|                      | Hazard ratio             | 95% CI                    | Hazard ratio    | 95% CI  | Hazard ratio | 95% CI  | P value |
| Age                  | 0.998                    | 0.977 to 1.019            | 0.862           | 1.003   | 0.802        | 1.003   | 0.750 |
| Gender               | 0.686                    | 0.394 to 1.194            | 0.183           | 0.856   | 0.583        | 0.776   | 0.374 |
| Anemia               | 0.506                    | 0.300 to 0.854            | 0.011           | 0.418   | 0.001        | 0.480   | 0.006 |
| MCV                  | 0.793                    | 0.288 to 2.180            | 0.653           | 0.878   | 0.801        | 0.678   | 0.451 |
| RDW                  | 0.803                    | 0.291 to 2.215            | 0.672           | 0.876   | 0.797        | 0.990   | 0.984 |
| Albumin              | 0.705                    | 0.440 to 1.130            | 0.147           | 0.606   | 0.037        | 0.567   | 0.019 |
| WBC                  | 1.127                    | 0.354 to 3.582            | 0.840           | 1.175   | 0.369        | 0.785   | 0.889 |
| Hs-CRP               | 1.701                    | 1.049 to 2.759            | 0.031           | 1.739   | 1.074        | 2.815   | 0.024 |
| T stage              | 1.376                    | 1.037 to 1.824            | 0.027           | 1.608   | 1.232        | 2.100   | 0.001 |
| Lymph node stage     | 0.869                    | 0.305 to 2.480            | 0.794           | 0.979   | 0.349        | 2.747   | 0.968 |
| Grade                | 0.818                    | 0.447 to 1.498            | 0.516           | 1.048   | 0.570        | 1.925   | 0.881 |
| Recurrence rate      | –                        | –                         | 0.958           | 0.504   | 0.897        | 1.822   | 0.897 |

### Table 3. Results of the multivariate Cox regression model.

| Variable at baseline | Recurrence-free survival | Progression-free survival | Overall survival | Reference category |
|----------------------|--------------------------|---------------------------|-----------------|--------------------|
|                      | Hazard ratio             | 95% CI                    | Hazard ratio    | 95% CI  | Hazard ratio | 95% CI  | P value |
| Anemia               | 0.474                    | 0.268 to 0.837            | 0.010           | 0.551   | 0.291        | 1.043   | 0.067 |
| Albumin              | –                        | –                         | 0.911           | 0.848   | 0.768        | 1.698   | 0.768 |
| Hs-CRP               | 1.355                    | 0.774 to 2.371            | 0.288           | 1.321   | 0.737        | 2.370   | 0.350 |
| T stage              | 1.204                    | 0.884 to 1.640            | 0.239           | 1.457   | 1.089        | 1.950   | 0.011 |

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS] [Index Copernicus]

This work is licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
and worse outcomes has been documented previously in BC patients. Our study sought to investigate this “old” topic and came to two novel conclusions.

First, the oncological outcomes of anemic NMIBC patients were significantly lower than non-anemic NMIBC patients, which did not differ significantly between anemic and non-anemic MIBC patients, so the correction of anemia may obtain the most benefits in stage Ta and T1 BC patients. We assumed that as tumor stage increased, the influence of the tumor itself, and the applied surgical procedures, would have a more significant impact on patient prognosis. Our findings were consistent with those of Shen et al. who reported that pretreatment anemia was associated with poorer survival in patients with stage I and II gastric cancer [25].

Figure 1. Kaplan-Meier plots of recurrence-free survival (A), progression-free survival (B), and overall survival (C) probability in patients with all stages of bladder cancer stratified by anemia.

Figure 2. Kaplan-Meier plots of recurrence-free survival (A, D), progression-free survival (B, E) and overall survival (C, F) probability in patients with non-muscle invasive and muscle-invasive bladder cancer stratified by anemia.
Second, we found that abnormal levels of baseline nutritional and inflammatory markers, such as albumin and CRP, correlated with anemia, and were also significantly associated with prognosis in BC patients. So the status of preoperative anemia can become a clue of baseline malnutrition or systemic inflammation and all of these conditions should be corrected in our clinical practice.

Our conclusions were limited by the scope of this study. First, the data of Eastern Cooperative Oncology Group (ECOG) PS and perioperative blood transfusion in BC patients were unavailable. Moreover, due to the inadequate baseline information and different grading systems applied to the included patients, the European Organization for Research and Treatment of Cancer risk scores, which were used to predict recurrence and progression in patients with stage Ta and T1 BC, could not be calculated. Thus their relationship with preoperative anemia was not assessed. Finally, an external independent validation of our data will be required to confirm our results in a prospective clinical study.

**Conclusions**

Preoperative anemia was a strong predictor of BC recurrence and may contribute to mortality at all stages of BC. Correction of anemia, combined with malnutrition and inflammation, before BC-directed treatment is initiated may improve outcomes of BC patients, particularly those with non-muscle-invasive bladder cancer.

**Reference:**

1. Ludwig H, Van Belle S, Barrett-Lee P et al: The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer, 2004; 40: 2293–306

2. Straus DJ, Testa MA, Sarokhan BJ et al: Quality-of-life and health benefits of early treatment of mild anemia: A randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies. Cancer, 2006; 107: 1909–17

**Figure 3.** Kaplan-Meier plots of recurrence-free survival, progression-free survival, and overall survival probability in patients with all stages of bladder cancer, stratified by albumin (A–C) and Hs-CRP (D–F).
3. Socinski MA, Zhang C, Herndon JE 2nd et al: Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: Analysis of factors influencing survival and toxicity. Ann Oncol, 2004; 15: 1033–41

4. Henry DH, Langer CJ, McKenzie RS et al: Hematologic outcomes and blood utilization in cancer patients with chemotherapy-induced anemia (CIA) pre- and post-national coverage determination (NCD): Results from a multicenter chart review. Support Care Cancer, 2012; 20: 2089–96

5. Ploeg M, Aben KK, Klemenczy LA: The present and future burden of urinary bladder cancer in the world. World J Urol, 2009; 27: 289–93

6. Ania BJ, Suman VI, Fairbanks VF et al: Prevalence of preoperative anemia in older people: An epidemiologic study in a well defined population. J Am Geriatr Soc, 1997; 45: 825–31

7. Gierth M, Mayr R, Aziz A et al: Perioperative anemia is associated with adverse outcome in patients with urothelial carcinoma of the bladder following radical cystectomy. J Cancer Res Clin Oncol, 2015; 141: 1819–26

8. Bruins HM, Arends T, Pelkman M et al: The prognostic value of preoperative laboratory parameters in patients undergoing radical cystectomy for bladder cancer. J Urol, 2013; 189: e584

9. Gondo T, Nakashima J, Ohno Y et al: Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy. Urology, 2012; 79: 1085–91

10. Belmilot J, Choueiri TK, Fougeray R et al: Prognostic factors in patients with advanced transitional cell carcinoma of the urethral tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol, 2010; 28: 1850–55

11. Rink M, Sharifi N, Fritzsche HM et al: Impact of perioperative anemia on oncologic outcomes of upper tract urothelial carcinoma treated with radical nephroureterectomy. J Urol, 2014; 191: 316–22

12. Babjuk M, Burger M, Zigeuner R et al: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2013. Eur Urol, 2013; 64: 639–53

13. Nutritional anaemias. Report of a WHO scientific group. World Health Organ Tech Rep Ser, 1968; 405: 5–37

14. Harrell FE Jr, Lee KL, Mark DB: Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med, 1996; 15: 361–87

15. Gireath JA, Stenehjem DD, Rodgers GM: Diagnosis and treatment of cancer-related anemia. Am J Hematol, 2014; 89: 203–12

16. Ferrucci L, Sembd RD, Guralnik JM et al: Proinflammatory state, hepcidin, and anemia in older persons. Blood, 2010; 115: 3810–16

17. Vaupel P, Kelleher DK, Hockel M: Oxygen status of malignant tumors: Pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol, 2001; 28: 29–35

18. Caro JJ, Salas M, Ward A, Goss G: Anemia as an independent prognostic factor for survival in patients with cancer: A systematic, quantitative review. Cancer, 2001; 91: 2214–21

19. Carson JL, Poses RM, Spence RK, Bonavita G: Severity of anaemia and operative mortality and morbidity. Lancet, 1988; 1: 727–29

20. Dunst J, Pigorsch S, Hansgen G et al: Low hemoglobin is associated with increased serum levels of vascular endothelial growth factor (VEGF) in cancer patients. Does anemia stimulate angiogenesis? Strahlenther Onkol, 1999; 175: 93–96

21. Dinne JR, Malone D, Tracy JK et al: Perioperative anemia: An independent risk factor for infection, mortality, and resource utilization in surgery. J Surg Res, 2002; 102: 237–44

22. Vaupel P, Mayer A: Hypoxia and anemia: Effects on tumor biology and treatment resistance. Transfus Clin Biol, 2005; 12: 5–10

23. Demetri GD: Anaemia and its functional consequences in cancer patients: Current challenges in management and prospects for improving therapy. Br J Cancer, 2001; 84(Suppl. 1): 31–37

24. Littlewood TI, Bajetta E, Nortier JW et al: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol, 2001; 19: 2865–74

25. Shen JG, Cheong JH, Hyung WJ et al: Pretreatment anemia is associated with poorer survival in patients with stage I and II gastric cancer. J Surg Oncol, 2005; 91: 126–30